Stayble Therapeutics AB
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.
Stayble Therapeutics AB (STABL) - Total Assets
Latest total assets as of September 2025: Skr9.90 Million SEK
Based on the latest financial reports, Stayble Therapeutics AB (STABL) holds total assets worth Skr9.90 Million SEK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Stayble Therapeutics AB - Total Assets Trend (2016–2024)
This chart illustrates how Stayble Therapeutics AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Stayble Therapeutics AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Stayble Therapeutics AB's total assets of Skr9.90 Million consist of 39.0% current assets and 61.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 23.7% |
| Accounts Receivable | Skr1.35 Million | 14.6% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr5.65 Million | 61.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Stayble Therapeutics AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Stayble Therapeutics AB's current assets represent 39.0% of total assets in 2024, a decrease from 69.4% in 2016.
- Cash Position: Cash and equivalents constituted 23.7% of total assets in 2024, down from 65.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 61.0% of total assets, an increase from 2.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 61.0% of total assets.
Stayble Therapeutics AB Competitors by Total Assets
Key competitors of Stayble Therapeutics AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Stayble Therapeutics AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Stayble Therapeutics AB generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Stayble Therapeutics AB is currently not profitable relative to its asset base.
Stayble Therapeutics AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.18 | 8.49 | 8.80 |
| Quick Ratio | 7.18 | 8.49 | 8.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr3.66 Million | Skr 5.09 Million | Skr 10.94 Million |
Stayble Therapeutics AB - Advanced Valuation Insights
This section examines the relationship between Stayble Therapeutics AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.48 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -57.3% |
| Total Assets | Skr9.26 Million |
| Market Capitalization | $856.35K USD |
Valuation Analysis
Below Book Valuation: The market values Stayble Therapeutics AB's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Stayble Therapeutics AB's assets decreased by 57.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Stayble Therapeutics AB (2016–2024)
The table below shows the annual total assets of Stayble Therapeutics AB from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr9.26 Million | -57.35% |
| 2023-12-31 | Skr21.70 Million | +13.35% |
| 2022-12-31 | Skr19.15 Million | -56.12% |
| 2021-12-31 | Skr43.64 Million | +142.48% |
| 2020-12-31 | Skr18.00 Million | +85.17% |
| 2019-12-31 | Skr9.72 Million | +7.95% |
| 2018-12-31 | Skr9.00 Million | -4.81% |
| 2017-12-31 | Skr9.46 Million | -22.22% |
| 2016-12-31 | Skr12.16 Million | -- |